Literature DB >> 8507756

Pharmacokinetics of new oral cephalosporins, including a new carbacephem.

M Fassbender1, H Lode, T Schaberg, K Borner, P Koeppe.   

Abstract

This review analyzes the pharmacokinetics of new oral cephalosporins, including esters, non-esters, and the carbacephem loracarbef, in healthy volunteers, as described in the literature and evaluated in several studies of our own. Single-dose studies have demonstrated considerable pharmacokinetic differences among these compounds. Cefixime, cefpodoxime proxetil, and cefetamet pivoxil are characterized by a low peak concentration and a prolonged half-life, while the other new agents have higher peak levels and shorter half-lives. Except for cefixime, the new oral cephalosporins are eliminated mainly by the kidneys. Pharmacokinetic studies in the elderly and in children indicate that the bioavailability of these agents is not influenced by age. Food increases the bioavailability of the ester cephalosporins but does not affect the absorption kinetics of the other new drugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8507756     DOI: 10.1093/clind/16.5.646

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Clinical and economic considerations in the use of third-generation oral cephalosporins.

Authors:  S T Chambers; D R Murdoch; M J Pearce
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 2.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

3.  Comparison of ceftibuten vs. amoxicillin/clavulanic acid as antibiotic prophylaxis in cholecystectomy and/or biliary tract surgery.

Authors:  H Orozco; J Sifuentes-Osornio; C Chan; H Medina-Franco; F Vargas-Vorackova; E Prado; J Arch
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

4.  Ceftibuten in paediatrics.

Authors:  R D Colucci; M Elliott; M B Affrime; N Zampaglione
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

5.  Pharmacokinetics of cefetamet in plasma and skin blister fluid.

Authors:  W Zimmerli; S Sansano; B Wittke
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 6.  Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections.

Authors:  P Ball
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-10       Impact factor: 3.267

Review 7.  Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; J A Balfour
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

8.  Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans.

Authors:  Ji-Hun Jang; Seung-Hyun Jeong; Hea-Young Cho; Yong-Bok Lee
Journal:  Pharmaceutics       Date:  2019-10-14       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.